Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy

N/ATerminatedNCT01195649

Bayer11 enrolled

Overview

The primary objective of this prospective, observational, post-marketing study is to evaluate the patient characteristics, pre-treatment and treatment duration in Renal Cell Carcinoma (RCC) patients who are candidates for systematic therapy and in whom a decision to treat with Nexavar® has been made under real-life practice settings and approved reimbursement restriction in Taiwan. Therefore, the main objective of the study is to collect data on: Prescription pattern: to determine the factors affecting compliance and duration of treatment with special attention given to education status, demography, disease details, pre-treatment, concomitant medication and other baseline data Nexavar® treatment and efficacy data Adverse events using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

Study Type

OBSERVATIONAL

Enrollment

Conditions

Carcinoma, Renal Cell

Interventions

Sorafenib (Nexavar, BAY43-9006)DRUG

Patients under daily life treatment according to local drug information

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with diagnosis of advanced Renal Cell Carcinoma (RCC) and decision taken by the investigator to prescribe Nexavar® under Taiwan reimbursement guideline * Patients must have a life expectancy of at least 8 weeks Exclusion Criteria: * Exclusion criteria must follow the approved local product information. * Patients were lost to follow-up if no follow-up visit and no final assessment of Nexavar® was documented.

Outcomes

Primary Outcomes

Evaluation of Safety and Efficacy of treatments and average doses that are used for patients with Renal Cell Carcinoma (collection of number of adverse events)

Time frame: After one year

Evaluation of Safety and Efficacy of treatments and average doses that are used for patients with Renal Cell Carcinoma (collection of changes in tumor status)